Skip to main content
North China Pharmaceutical Company.Ltd logo

North China Pharmaceutical Company.Ltd — Investor Relations & Filings

Ticker · 600812 ISIN · CNE000000D16 LEI · 300300MGIO00O7A1AV65 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,891 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600812

About North China Pharmaceutical Company.Ltd

http://www.ncpc.com.cn

North China Pharmaceutical Company Ltd. (NCPC) focuses on the research, development, and large-scale manufacturing of antibiotics, vitamins, and biopharmaceutical products. The company is a major producer of penicillin, streptomycin, and cephalosporins, maintaining a comprehensive portfolio of active pharmaceutical ingredients and finished dosage forms. Its core offerings include anti-infectives, cardiovascular treatments, and nutritional supplements. NCPC leverages advanced fermentation and chemical synthesis capabilities to serve global markets. The organization emphasizes innovation in biotechnology, specifically in the development of recombinant human serum albumin and monoclonal antibodies. Through integrated production processes and specialized research centers, the company addresses therapeutic needs in infectious diseases, metabolic health, and chronic care.

Recent filings

Filing Released Lang Actions
关于公司获得《药品注册证书》的公告
Regulatory Filings Classification · 88% confidence The document is a corporate announcement in Chinese regarding the company obtaining a drug registration certificate from the National Medical Products Administration. It contains no financial statements or report content but is a regulatory compliance announcement of a product approval. Therefore it does not fit specific financial report categories and falls under general regulatory filings.
2026-05-22 Chinese
北京德恒律师事务所关于华北制药股份有限公司二〇二五年年度股东会的见证法律意见
Regulatory Filings Classification · 74% confidence The document is a legal opinion letter issued by a law firm (DeHeng) regarding the convening, procedures, attendance qualifications, voting process, and voting results of the 2025 annual general meeting of 华北制药股份有限公司. It is not the annual report itself, an earnings release, or a presentation; rather it is a counsel’s certification/attestation on meeting legality and vote outcomes. Under the “Certification Rule,” such a lawyer’s attestation letter should be classified under the fallback category for miscellaneous regulatory filings, not as the report or the voting‐results announcement itself. Therefore, the correct classification is RNS (Regulatory Filings).
2026-05-20 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 97% confidence The document is titled “2025年年度股东会决议公告” and provides detailed resolutions passed at the Annual General Meeting, including attendance figures and vote counts for each proposal. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2026-05-20 Chinese
第十二届董事会第一次会议决议公告
Board/Management Information Classification · 90% confidence The document is an announcement by Huabei Pharmaceutical of the resolutions passed at the first meeting of its 12th Board of Directors, including elections of the chairman, vice chairman, committee members, and appointments of the general manager, deputy managers, board secretary, and securities affairs representative. It details changes in board composition and senior management roles. This matches the Board/Management Information category.
2026-05-20 Chinese
关于选举职工董事的公告
Board/Management Information Classification · 88% confidence The document is a short announcement by the company regarding the election of an employee (staff) director to its board, including the name, term, and resume. This clearly falls under ‘Board/Management Information’ as it relates to changes in the board of directors. There is no detailed financial report or shareholder vote results beyond the board election itself, so the appropriate classification is MANG.
2026-05-20 Chinese
关于召开2025年度暨2026年第一季度业绩说明会的公告
Regulatory Filings Classification · 80% confidence The document is an announcement about the scheduling and details of an upcoming earnings explanation meeting (业绩说明会) for the 2025 annual and 2026 first quarter results. It references that the 2025 annual report and 2026 Q1 report have already been published on earlier dates. The document provides logistics for the meeting, participation instructions, and contact information. It does not contain actual financial statements or detailed financial analysis itself, but rather serves as a notice for an investor call or presentation event. Given the nature of the document as an announcement for an earnings explanation meeting, it best fits the category of a Call Transcript (CT) or Investor Presentation (IP). However, since it is only an announcement of the meeting and not the transcript or presentation itself, and the document length is short (1284 characters), it is not the transcript or presentation but an announcement of the event. The closest fitting category is Regulatory Filings (RNS) as a fallback for announcements that do not fit other categories, since it is not a transcript or presentation itself. Therefore, the classification is RNS with moderate confidence.
2026-05-07 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.